Data from the vaccine coverage survey are available at <https://osf.io/c8xuq/>. Absentee data cannot be shared publicly because of protections under the Family Educational Rights and Privacy Act. Researchers may apply for access to absentee data from Oakland Unified School District at <https://www.ousd.org/Page/1016> and from West Contra Costa Unified School District at <https://www.wccusd.net/page/545>. Influenza hospitalization data may be requested from the California Emerging Infections Program (<info@ceip.us>; <https://ceip.us/contact/>).

Introduction {#sec007}
============

Seasonal influenza contributes substantially to hospitalization and mortality, especially among infants and the elderly \[[@pmed.1003238.ref001]\]. To prevent the spread of influenza, seasonal influenza vaccination of all individuals over 6 months of age has been recommended by the Advisory Committee on Immunization Practices (ACIP) in the US since 2010 \[[@pmed.1003238.ref002]\]. The effectiveness of seasonal influenza vaccines varies from year to year depending on the quality of the influenza virus strain match and whether antigenic drift occurs between the time when the vaccine is manufactured and the start of the seasonal influenza epidemic, among other factors.

Because school-aged children are responsible for the greatest proportion of community-wide influenza transmission, efforts to increase vaccination among children are likely to have the largest impact on transmission \[[@pmed.1003238.ref003]--[@pmed.1003238.ref008]\]. Mathematical models estimate that vaccinating at least 50%--70% of school-aged children against influenza can prevent an influenza epidemic by producing herd immunity (i.e., "indirect effects") \[[@pmed.1003238.ref009],[@pmed.1003238.ref010]\]. In recent years, influenza vaccination coverage in the US has ranged from 54% to 62% among elementary-school-aged children and from 37% to 44% among adults \[[@pmed.1003238.ref011],[@pmed.1003238.ref012]\], lower than the Healthy People 2020 goal of 70% coverage \[[@pmed.1003238.ref013]\]. Mathematical models project that influenza vaccination coverage of 80% in children would reduce influenza hospitalizations among children by 42% and among adults by approximately 20% \[[@pmed.1003238.ref014]\].

School-located influenza vaccination (SLIV) programs have been proposed as a strategy to increase influenza vaccination coverage among children \[[@pmed.1003238.ref015]\]. Prior studies reported that SLIV programs increased influenza vaccination \[[@pmed.1003238.ref016]--[@pmed.1003238.ref025]\] and decreased school absences \[[@pmed.1003238.ref016]--[@pmed.1003238.ref019],[@pmed.1003238.ref026]--[@pmed.1003238.ref028]\] and student illnesses \[[@pmed.1003238.ref016],[@pmed.1003238.ref019]\], and some studies report that the economic benefits of such programs likely outweigh the cost of program delivery \[[@pmed.1003238.ref029],[@pmed.1003238.ref030]\]. There is some evidence that SLIV programs can produce community-wide indirect effects among preschool-aged children and adults; however, studies have produced conflicting results \[[@pmed.1003238.ref020],[@pmed.1003238.ref021],[@pmed.1003238.ref031]--[@pmed.1003238.ref033]\]. Many prior SLIV evaluations used study designs that are subject to confounding \[[@pmed.1003238.ref017],[@pmed.1003238.ref018],[@pmed.1003238.ref020],[@pmed.1003238.ref021],[@pmed.1003238.ref026]--[@pmed.1003238.ref028],[@pmed.1003238.ref031]--[@pmed.1003238.ref033]\]; those that have used more rigorous designs did not measure health outcomes \[[@pmed.1003238.ref023]--[@pmed.1003238.ref025],[@pmed.1003238.ref034],[@pmed.1003238.ref035]\] or enrolled small numbers of schools \[[@pmed.1003238.ref016],[@pmed.1003238.ref019]\]. To our knowledge, no prior studies have rigorously measured the impacts of large-scale SLIV interventions on student and community-wide health outcomes over multiple years.

Here, we report the findings of a 4-year evaluation of a SLIV program delivered to ≥95 preschools and elementary schools in Oakland, California, a diverse, urban, predominantly low-income city in northern California. The intervention was delivered city-wide to reduce influenza among elementary school children and to interrupt community-wide influenza transmission through herd effects. Using a matched cohort design and 3 independent data sources, we measured whether the intervention was associated with increased student influenza vaccination and decreased incidence of community-wide laboratory-confirmed influenza hospitalization and school absences.

Methods {#sec008}
=======

Ethical statement {#sec009}
-----------------

This study was approved by the Committee for Protection of Human Subjects at the University of California, Berkeley (Protocols 2014-01-5960 and 2016-12-9406). To measure influenza vaccination coverage, we invited caregivers of students to participate in a survey. Caregivers received a letter from the school district describing the purpose of the survey and providing details about the optional and anonymous nature of the survey. The UC Berkeley Committee for Protection of Human Subjects granted study investigators a waiver of documented informed consent to carry out the survey because in 2 years of pilot surveys in which we requested documented informed consent, the complexity of consent forms contributed to very low response rates that prevented us from collecting a sufficiently large sample to estimate vaccination coverage.

SLIV intervention {#sec010}
-----------------

The Shoo the Flu intervention ([http://www.shootheflu.org](http://www.shootheflu.org/)) delivered free influenza vaccinations at all public and charter elementary schools in Oakland Unified School District (OUSD, the "intervention district") in the city of Oakland, California, and offered delivery to all other preschools and elementary schools in Oakland, including non-OUSD charter schools and private schools. Vaccinations were delivered prior to the start of influenza season from 2014 through 2018 (influenza seasons 2014--2015, 2015--2016, 2016--2017, and 2017--2018). OUSD enrolls a diverse, urban population of approximately 53,000 students, including over 26,000 elementary school students (kindergarten through grade 5). Over 70% of students in this district are from low-income households, and half of students speak a language other than English in their home. The intervention aimed to increase influenza vaccination coverage among primarily elementary-school-aged children in order to reduce influenza among elementary school children and to produce indirect effects protecting other age groups in the community. In its first 2 years, the intervention deployed a mass media campaign in the Oakland area, including advertisements in the subway, bus shelters, billboards, and newspapers, as well as through digital media. The intervention did not carry out promotion efforts outside of the Oakland area, although it is possible that residents of areas near Oakland were exposed to Shoo the Flu media. Caregivers of the students provided written consent for vaccination, and this consent process was separate from consent to participate in the evaluation of the intervention. Children were eligible for vaccination regardless of their insurance status. From 2014 to 2018, between 95 and 138 elementary schools and preschools participated in Shoo the Flu, and each year the intervention vaccinated between 7,502 and 10,106 students (22%--28% of eligible students) ([S1 Table](#pmed.1003238.s023){ref-type="supplementary-material"}).

Influenza vaccine effectiveness during the intervention {#sec011}
-------------------------------------------------------

In influenza seasons 2014--2015 and 2015--2016, the intervention offered the live attenuated influenza vaccine (LAIV) to students and the inactivated influenza vaccine (IIV) to students with LAIV contraindications, consistent with ACIP recommendations \[[@pmed.1003238.ref036],[@pmed.1003238.ref037]\]. The intervention also offered IIV to school staff and teachers. In early 2016, the ACIP changed its recommendation for children aged 2 to 8 years from LAIV to IIV due to concerns about the low effectiveness of LAIV in the 2 prior seasons \[[@pmed.1003238.ref038]\]. In influenza seasons 2016--2017 and 2017--2018, the intervention offered only IIV. The seasonal influenza vaccine delivered by the intervention had low effectiveness in 2014--2015 and 2015--2016 and moderate effectiveness in 2016--2017 and 2017--2018 ([Fig 1](#pmed.1003238.g001){ref-type="fig"}) \[[@pmed.1003238.ref039],[@pmed.1003238.ref040]\].

![Estimated influenza vaccine effectiveness from 2014 to 2018.\
Vaccine effectiveness = (1 − OR) × 100%, where OR is the odds ratio for testing positive for influenza among individuals vaccinated for influenza compared to those who were not vaccinated. Estimates for influenza seasons 2014--2015 and 2015--2016 are for children 2--8 years; estimates for seasons 2016--2017 and 2017--2018 are for children 6 months to 8 years of age. Some strains for which there were not stable estimates for children 2--18 years are excluded from this plot. Source: US Influenza Vaccine Effectiveness Network. \*Dominant strain circulating each season.](pmed.1003238.g001){#pmed.1003238.g001}

Study design {#sec012}
------------

This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline ([S1 Checklist](#pmed.1003238.s001){ref-type="supplementary-material"}).

The SLIV intervention was offered to all preschools and elementary schools in the city of Oakland with the goal of delivering SLIV to the largest number of schools possible in order to interrupt influenza transmission (i.e., produce indirect effects) in the city. For this reason, it was infeasible to use a cluster-randomized design because all schools in the district were offered the intervention. The study used a matched cohort design to evaluate the SLIV intervention program using a retrospective analysis of prospectively collected data \[[@pmed.1003238.ref041]\]. We drew on multiple independent data sources to assess a full range of outcomes that could have been affected by the SLIV intervention: (1) influenza vaccination coverage, (2) influenza hospitalizations in the community, and (3) all-cause and illness-specific school absence rates among elementary school students. We conducted a survey of a sample of student caregivers to measure influenza vaccination coverage and analyzed existing school absence and influenza hospitalization records. In some cases, outcome assessment required slightly different designs and estimators, as we describe below.

The matched design focused on the vaccination coverage survey. We first selected from comparison school districts among San Francisco Bay Area districts that had at least 4 elementary schools and had pre-intervention school-level characteristics similar to those of the intervention district. We restricted possible comparison districts to those with boundaries separated by at least 5 miles from the intervention district to minimize contamination. Though the intervention was provided to some private and charter schools in the intervention city, the study population was restricted to public elementary schools in the intervention city school district because pre-intervention data were not readily available to identify suitable comparison private or non-district charter schools.

We used a genetic multivariate matching algorithm \[[@pmed.1003238.ref042]\] to pair-match schools in the intervention district with schools in each candidate comparison district. The matching algorithm used the following pre-intervention school-level characteristics: mean enrollment, class size, parental education, academic performance index scores, California standardized test scores, school-level percentage of English language learners, and school-level percentage of students receiving free lunch at school. We excluded preschools from this evaluation because the availability of preschools and enrollment criteria varied from school district to school district, complicating comparisons between districts. We identified West Contra Costa Unified School District (WCCUSD) as the best nearby comparison district because, on average, it had the smallest generalized Mahalanobis distance between paired schools \[[@pmed.1003238.ref042]\] and a sufficient number of elementary schools (*N* = 34 schools, grades K through 6) in the district to ensure adequate statistical power. The absolute value of the standardized difference was under 50 for most variables, indicating that the matching produced good quality school pair matches \[[@pmed.1003238.ref043]\] (see [S1 Appendix](#pmed.1003238.s002){ref-type="supplementary-material"} for further details).

Analyses of influenza hospitalization and school absences leveraged the matched design but used a slightly different approach tailored to each outcome. Because the intention was to measure community-wide indirect effects of SLIV on influenza hospitalization, we included hospitalizations of all residents of zip codes within the intervention and comparison district school catchment areas, including zip codes that were partially within the district boundary. To measure impacts on school absences, we prespecified inclusion of all public elementary schools enrolling kindergarten to grade 5 (K--5) (50 intervention schools, 34 comparison schools) rather than the matched subset used to design the vaccine coverage survey in order to maximize precision.

Outcomes and data sources {#sec013}
-------------------------

### Vaccine coverage survey {#sec014}

We conducted 2 cross-sectional surveys of student caregivers to measure caregiver-reported student influenza vaccination, including vaccine type and vaccine provider. A survey in March 2017 measured vaccination for influenza seasons 2014--2015, 2015--2016, and 2016--2017, and a survey in March 2018 measured vaccination for season 2017--2018. We distributed the surveys in 22 of the 34 matched school pairs (22 K--5 schools in the intervention district and 22 K--6 schools in the comparison district). In all classrooms in each school, teachers distributed anonymous paper surveys to students to share with their caregivers. The survey was conducted independently from the intervention and allowed caregivers to report student influenza vaccination at any location.

### Laboratory-confirmed influenza hospitalizations {#sec015}

We obtained counts of all laboratory-confirmed influenza hospitalizations, intensive care unit admissions, and deaths among hospitalized patients, and the duration of influenza hospitalizations from zip codes within the intervention and comparison school districts in influenza seasons 2011--2012 through 2017--2018 from the CDC-sponsored California Emerging Infections Program \[[@pmed.1003238.ref044]\].

### School absence records {#sec016}

We obtained records of absentee data for each student on each school day for school years 2011--2012 through 2017--2018 from all public elementary schools in each school district. Absences were classified by student grade, race/ethnicity, and absence type (all-cause absences versus illness-specific absences). Absences were classified as related to illness or not based on parent report, as recorded by each school district.

Statistical power calculations for each outcome are available in [S2 Appendix](#pmed.1003238.s003){ref-type="supplementary-material"}.

Statistical analysis {#sec017}
--------------------

Unless otherwise specified, analyses were conducted in R version 3.6.1 \[[@pmed.1003238.ref045]\]. Our pre-analysis plan, selected datasets, and replication scripts are available through the Open Science Framework (<https://osf.io/c8xuq/>). We defined overall effects as the difference in outcomes between elementary-school-aged individuals (both those who did and did not participate in the intervention) in the intervention versus comparison site, and indirect effects as the difference in outcomes between individuals in the intervention versus comparison site ([Fig 2](#pmed.1003238.g002){ref-type="fig"}). We estimated indirect effects among non-elementary-school-aged individuals (≤4 years or ≥13 years) and elderly individuals (≥65 years).

![Schematic of types of effects estimated in this study.\
The "intervention effect" compares influenza vaccination coverage and school absence rates among elementary school children aged 5--12 years enrolled in schools participating in the intervention and schools in the comparison site. The "indirect effect" compares influenza hospitalization rates between individuals in zip codes overlapping with the intervention and comparison school districts; we estimated indirect effects among non-elementary-school-aged individuals (0--4 or ≥13 years) and elderly individuals (≥65 years). The "overall effect" compares influenza hospitalization rates among all individuals in zip codes overlapping with the intervention and comparison school districts; it averages across the intervention effect and indirect effect.](pmed.1003238.g002){#pmed.1003238.g002}

Definition of influenza seasons {#sec018}
-------------------------------

Because influenza season timing varies from year to year, we prespecified a data-derived definition of influenza season in order to conduct our analysis during the weeks in which the influenza epidemic occurred locally each year. Under this definition, influenza season started when there were at least 2 consecutive weeks in which the percentage of medical visits for influenza-like illness in California as reported by the California Department of Public Health \[[@pmed.1003238.ref046]\] exceeded a cutoff, and the season ended when there were at least 2 consecutive weeks in which the percentage was less than or equal to the cutoff. In our pre-analysis plan, we set the cutoff at 2%. Post hoc, we examined seasons defined using cutoffs of 2%, 2.5%, and 3% and selected 2.5% as the primary definition because, in some seasons, the 2% cutoff included weeks as early as September and as late as June, and we felt that the 2.5% cutoff best captured seasonal variation in peak influenza-like illness ([S1 Fig](#pmed.1003238.s007){ref-type="supplementary-material"}). We made this change only considering overall seasonal patterns for influenza-like illness before estimating any program effects.

### Influenza vaccination coverage {#sec019}

We estimated influenza vaccination coverage and 95% confidence intervals using robust sandwich standard errors that accounted for clustering at the school level \[[@pmed.1003238.ref047]\]. We estimated differences in vaccination coverage between districts using a generalized linear model that adjusted for student race/ethnicity and caregiver's education level and estimated standard errors that accounted for clustering within matched school pairs. We restricted the analysis to grades K--5 because the intervention district's elementary schools did not include sixth grade. To assess possible selection bias among the sample of caregivers who responded to the survey, we also estimated vaccination coverage after standardizing the distributions of race/ethnicity and education in the sample to the pre-intervention percentages using data from the California Department of Education for the 44 participating schools and for the entire districts (see details in [S3 Appendix](#pmed.1003238.s004){ref-type="supplementary-material"}).

### Laboratory-confirmed influenza hospitalization {#sec020}

To estimate the cumulative incidence of influenza hospitalization, we obtained age- and race-specific population counts from the 2010 US Census in the same set of zip codes used to identify influenza cases. We also obtained more recent annual population counts from the 5-year American Community Survey (ACS). Because counts were similar between both data sources and the ACS did not provide population counts by race and age in years, we used the US Census data in our primary analyses. We fit log-linear Poisson models to estimate cumulative incidence using a log population offset and adjusting for age, sex, and race \[[@pmed.1003238.ref048]\]. To control for pre-season differences between districts, we estimated the difference-in-differences (DID), defined as the difference in incidence in the intervention district prior to (2011--2013) and during the intervention minus the difference in incidence in the comparison district prior to and during the intervention. Examination of pre-intervention influenza hospitalization patterns indicated that the equal trends assumption was reasonable ([Fig 3](#pmed.1003238.g003){ref-type="fig"}; [S4 Appendix](#pmed.1003238.s005){ref-type="supplementary-material"} Figs A and B). The DID parameter eliminates any time-invariant confounding and accounts for differences in pre-intervention outcomes between districts \[[@pmed.1003238.ref049]\]. We obtained standard errors for each quantity using the delta method. Consistent with our pre-analysis plan, we did not estimate DID for intensive care unit admission on its own or for influenza mortality because these are rare outcomes, and we were likely to be underpowered to detect an effect. We also estimated outcomes in the peak week of the influenza season, defined as the week with the highest rate of influenza hospitalization in the study site. We performed a sensitivity analysis using the following alternative influenza season cutoffs: (1) 2 consecutive weeks in which the percentage of medical visits for influenza-like illness exceeded (season start) or fell below (season end) 2% or 3% (instead of 2.5%) and (2) October 1 (season start) to April 30 (season end) each year. The latter classification is conservative in that it often includes many weeks of the year with limited influenza-like illness in the influenza season.

![Weekly incidence of inpatient laboratory-confirmed influenza prior to and during the intervention among all ages.\
Weekly incidence proportion of laboratory-confirmed influenza hospitalizations (including intensive care unit admissions) between October 1 and April 30 of each year. Hospitalizations included school district residents tested at healthcare facility laboratories located in zip codes overlapping with OUSD and WCCUSD (Alameda County Public Health Department, Children's Hospital Oakland, Contra Costa Public Health Department, Kaiser Permanente, Sutter Health). Population denominators were obtained from the 2010 US Census using the same set of zip codes.](pmed.1003238.g003){#pmed.1003238.g003}

### School absence rates {#sec021}

We restricted the primary analysis of school absence rates to school days when both districts were in session. In addition, we restricted to school days that occurred during influenza season because we did not expect the intervention to influence influenza and absenteeism outside of that period. We also estimated outcomes in the peak week of the influenza season, defined as the week with the highest proportion of influenza-like illness visits in California when school was in session. Examination of pre-intervention school absence patterns indicated that the equal trends assumption required for valid DID analysis was reasonable ([S4 Appendix](#pmed.1003238.s005){ref-type="supplementary-material"} Figs C and D). We estimated DID in mean absence rates using linear regression models and adjusted for available time-varying covariates: student race, grade, and month of absence. We did not adjust for pre-intervention school characteristics (i.e., those used in the matching of school pairs) because they were time-invariant and thus would have no effect on DID estimates. We calculated 95% confidence intervals using robust standard errors that accounted for clustering within schools \[[@pmed.1003238.ref047]\]. We estimated the difference in total student absences during influenza season by multiplying DID estimates and confidence interval bounds by the total student enrollment and the number of school days in each influenza season.

Differential measurement error could have occurred if absences were recorded with different levels of accuracy between the intervention and comparison site. To detect potential differential measurement error of school absences, we conducted a negative control analysis \[[@pmed.1003238.ref050]\] using the school days in August, September, May, and June; these months were prior to the delivery of vaccines at school and outside of influenza season, when we did not expect to see an effect of the intervention \[[@pmed.1003238.ref014]\]. We also performed a sensitivity analysis using the following alternative influenza season cutoffs: (1) 2 consecutive weeks in which the percentage of medical visits for influenza-like illness exceeded (season start) or fell below (season end) 2% or 3% and (2) week 40 of each year to week 20 of the next year. The latter classification is used in influenza surveillance by the CDC, but it often includes periods with limited influenza-like illness.

As we describe in the Results, the negative control analysis indicated possible differential measurement error of school absences, so we performed a post hoc probabilistic bias analysis to quantify the possible influence of outcome misclassification on our results \[[@pmed.1003238.ref051]\]. In this analysis, we assumed a range of possible values of the sensitivity and specificity of absence classification based on conversations with data managers in each school district ([S5 Appendix](#pmed.1003238.s006){ref-type="supplementary-material"} Table A and Fig A). For example, in the comparison district, we assumed that the sensitivity of all-cause absences (the probability that a true absence of any cause was classified as such by the school district) was most likely to be close to 1 and in very few instances was less than 0.50. In a simulation, we drew from the distributions of sensitivity and specificity to calculate the bias-corrected absence rate correcting for possible misclassification under a range of plausible scenarios; we repeated this process 1,000 times to obtain distributions of bias-corrected DID estimates ([S5 Appendix](#pmed.1003238.s006){ref-type="supplementary-material"}). We focused on outcome misclassification because exposure misclassification was highly unlikely, and our DID analysis accounted for measured and time-invariant unmeasured confounders.

To examine impact across different levels of program participation among the 50 SLIV intervention schools, we predicted the mean absence rate (*Y*) setting each school's value to each observed level of school participation in SLIV (*A*) and adjusting for the school-level covariates student race/ethnicity, the percentage of students in each grade, average enrollment, mean class size, mean parent education level, percentage of English language learners, percentage of students receiving free lunch, mean 2012 Academic Performance Index score, mean 2013 Academic Performance Index score, and mean California Standards Test scores (*W*) (∑~*w*~E\[*Y\|A = a, W = w*\]*P*(*W = w*)). We used an ensemble machine learning algorithm that flexibly adjusted for covariates correlated with the outcome (*p* \< 0.1) in statistical models. The algorithm included the following estimation methods: the simple mean, main effects generalized linear models, stepwise logistic regression, Bayesian generalized linear models \[[@pmed.1003238.ref052]\], generalized additive models \[[@pmed.1003238.ref053]\], elastic net regression \[[@pmed.1003238.ref054]\], random forest \[[@pmed.1003238.ref055]\], and gradient boosting \[[@pmed.1003238.ref056]\].

Results {#sec022}
=======

Influenza vaccine coverage {#sec023}
--------------------------

Many measured pre-intervention characteristics were similar in populations residing in the catchment areas of the intervention and comparison schools ([Table 1](#pmed.1003238.t001){ref-type="table"}). The median household income was lower in the intervention site (\$51,849, 95% CI \$50,460, \$53,238) than the comparison site (\$61,596, 95% CI \$61,596, \$63,530). Comparing the intervention site to the comparison site, the proportion black/African American residents was higher (26%, 95% CI 25%, 27%, versus 17% 95% CI 16%, 18%), and the percentage of Hispanic or Latino residents was lower (26%, 95% CI 25%, 27%, versus 33%, 95% CI 32%, 35%). The percentage of residents with a bachelor's degree or higher was 15% (95% 12%, 17%) in the intervention site and 6% (95% CI 4%, 8%) in the comparison site.

10.1371/journal.pmed.1003238.t001

###### Pre-intervention characteristics of the population in the school district catchment areas.

![](pmed.1003238.t001){#pmed.1003238.t001g}

  Characteristic                                                         Intervention (95% CI)     Comparison (95% CI)
  ---------------------------------------------------------------------- ------------------------- -------------------------
  Median household income (dollars)                                      51,849 (50,460, 53,238)   61,596 (59,662, 63,530)
  Households below the poverty level (%)                                 21 (20, 22)               15 (13, 16)
  Highest education level (%)                                                                       
      Less than high school                                              16 (15, 18)               14 (12, 17)
      High school graduate                                               24 (21, 26)               30 (25, 34)
      Some college or associate's degree                                 46 (43, 48)               50 (46, 55)
      Bachelor's degree or higher                                        15 (12, 17)               6 (4, 8)
  Children attending kindergarten in private versus public schools (%)                              
      Public                                                             87 (81, 92)               86 (80, 92)
      Private                                                            13 (8, 19)                14 (8, 20)
  Children attending grade 1--4 in private versus public schools (%)                                
      Public                                                             89 (86, 92)               84 (79, 88)
      Private                                                            11 (8, 14)                16 (12, 21)
  Children attending grade 5--8 in private versus public schools (%)                                
      Public                                                             89 (86, 91)               87 (83, 91)
      Private                                                            11 (9, 14)                13 (9, 17)
  Race (%)                                                                                          
      White                                                              41 (40, 42)               48 (47, 50)
      Black or African American                                          26 (25, 27)               17 (16, 18)
      Asian                                                              16 (16, 17)               19 (18, 20)
      Other race                                                         9 (8, 10)                 8 (7, 9)
      Native Hawaiian and other Pacific Islander                         1 (0, 1)                  0 (0, 1)
      2 or more races                                                    6 (6, 7)                  6 (5, 7)
  Hispanic or Latino ethnicity (%)                                       26 (25, 27)               33 (32, 35)

Data from the 3-year 2013 American Community Survey subset by school district boundaries.

In March 2017, field staff disseminated 8,121 surveys in 22 schools in OUSD and 10,054 surveys in 22 schools in WCCUSD ([S2 Fig](#pmed.1003238.s008){ref-type="supplementary-material"}). The response rates were 28% (*N* = 2,246 surveys) in OUSD and 38% in WCCUSD (*N* = 3,824). One school in OUSD withdrew, and we excluded its matched pair from analyses comparing the 2 districts. In March 2018, the same schools were invited to participate, and the response rates were similar. In each survey, 32%--40% of respondents had a higher than high school level of education; the education level among survey respondents was lower than in the school district catchment areas as a whole ([Table 1](#pmed.1003238.t001){ref-type="table"}), which included households that participated in this survey as well as those whose children attended private schools. Approximately 22%--27% of respondents' primarily language spoken at home was Spanish. The most common student race/ethnicity was Latino (36%--41% in intervention; 50%--51% in comparison), followed by Asian (22%--25% in intervention; 16%--17% in comparison) and black/African American (16% in intervention; 10% in comparison).

Influenza vaccination coverage (from any source) among K--5 elementary students did not differ statistically between the intervention and comparison districts in the first 2 years of the SLIV intervention but was higher in the intervention district in the latter 2 years of the intervention. In relation to the comparison district, influenza vaccination coverage in the intervention district was 7% (95% CI 4%, 11%; *p* \< 0.001) higher in influenza season 2016--2017 and 11% (95% CI 7%, 15%; *p* \< 0.001) higher in season 2017--2018; differences were statistically significant ([Table 2](#pmed.1003238.t002){ref-type="table"}). Standardizing vaccination coverage by student race and parent education produced similar results ([S3 Fig](#pmed.1003238.s009){ref-type="supplementary-material"}). The percentage of elementary students vaccinated for influenza at school was 14% in 2014--2015, 23% in 2015--2016, 24% in 2016--2017, and 26% in 2017--2018 ([S4 Fig](#pmed.1003238.s010){ref-type="supplementary-material"}; [S2 Table](#pmed.1003238.s024){ref-type="supplementary-material"}). The majority of students not vaccinated at school were vaccinated at a doctor's office or health clinic. In 2014--2015 and 2015--2016, seasons when IIV and LAIV were available, 48%--52% of students received IIV and 12% of students received LAIV in the comparison site, and 36%--39% of students received IIV and 19%--23% of students received LAIV in the intervention site ([S5 Fig](#pmed.1003238.s011){ref-type="supplementary-material"}; [S3 Table](#pmed.1003238.s025){ref-type="supplementary-material"}). When adjusting for school-level characteristics, influenza vaccination coverage did not vary by the percentage of students participating in SLIV in each school ([S6 Fig](#pmed.1003238.s012){ref-type="supplementary-material"}).

10.1371/journal.pmed.1003238.t002

###### Caregiver-reported influenza vaccination coverage among elementary school students during the school-located influenza vaccination intervention period.

![](pmed.1003238.t002){#pmed.1003238.t002g}

  Season                                             Intervention   Comparison    Intervention minus comparison[^a^](#t002fn001){ref-type="table-fn"}, percent (95% CI)   *p*-Value                   
  -------------------------------------------------- -------------- ------------- --------------------------------------------------------------------------------------- ------------- ------------- ---------
  2014--2015[^b^](#t002fn002){ref-type="table-fn"}   2,246          59 (56, 63)   3,824                                                                                   64 (61, 67)   −5 (−9, −1)   0.017
  2015--2016[^b^](#t002fn002){ref-type="table-fn"}   2,246          68 (65, 70)   3,824                                                                                   66 (64, 68)   1 (−2, 4)     0.416
  2016--2017[^b^](#t002fn002){ref-type="table-fn"}   2,246          64 (61, 67)   3,824                                                                                   56 (54, 59)   7 (4, 11)     \<0.001
  2017--2018[^c^](#t002fn003){ref-type="table-fn"}   2,421          64 (60, 69)   4,086                                                                                   53 (51, 56)   11 (7, 15)    \<0.001

^a^Difference in percentage vaccinated adjusting for student race and caregiver education level. All confidence intervals were calculated using robust standard errors accounting for clustering at the school level.

^b^Influenza vaccination was reported by caregivers in March 2017.

^c^Influenza vaccination was reported by caregivers in March 2018.

Influenza hospitalization {#sec024}
-------------------------

In the 3 influenza seasons before the intervention, the age-standardized incidence of influenza-related hospitalization was similar between the intervention and comparison districts ([Fig 3](#pmed.1003238.g003){ref-type="fig"}). In 2014--2015 and 2015--2016, the incidence of influenza hospitalization was not statistically different between the intervention and comparison districts in any age group ([Fig 3](#pmed.1003238.g003){ref-type="fig"}; [S4 Table](#pmed.1003238.s026){ref-type="supplementary-material"}). In 2016--2017 and 2017--2018, hospitalization incidence was lower in the intervention versus comparison district in all age groups. Among non-elementary-aged individuals (0--4 or ≥13 years), the DID in the cumulative incidence of influenza hospitalization was −17 (95% CI −30, −4; *p* = 0.008) in 2016--2017 and −37 (95% CI −54, −19; *p* \< 0.001) in 2017--2018 ([Fig 3](#pmed.1003238.g003){ref-type="fig"}; [S4 Table](#pmed.1003238.s026){ref-type="supplementary-material"}) in the intervention versus comparison district. Among individuals aged at least 65 years, the DID in the cumulative incidence of influenza hospitalization was −73 (95% CI −147, 1; *p* = 0.054) in 2016--2017 and −160 (95% CI −267, −53; *p* = 0.004) in 2017--2018 ([Fig 4](#pmed.1003238.g004){ref-type="fig"}; [S4 Table](#pmed.1003238.s026){ref-type="supplementary-material"}). Results were similar in analyses restricted to the peak week of influenza hospitalization ([S7 Fig](#pmed.1003238.s013){ref-type="supplementary-material"}).

![Total and indirect effects on cumulative incidence of inpatient laboratory-confirmed influenza during influenza season.\
Cumulative incidence of laboratory-confirmed influenza hospitalization (including intensive care unit admissions) during influenza season. Difference-in-differences estimates represent the difference between intervention and control groups in their change in incidence from the 3 pre-program influenza seasons (2011--2013) to each program season, which removes any time-invariant differences between groups (measured or unmeasured). The left *y-*axis presents the difference-in-differences in the cumulative incidence per 100,000. The right *y*-axis presents the difference-in-differences in the total hospitalizations, which was calculated as the product of the difference-in-differences in the cumulative incidence and the population of the intervention site. For both *y*-axes, triangles represent indirect effects and circles represent overall effects. Parameters were estimated using a log-linear Poisson model with an offset for population size, and were further adjusted for age, race, and sex. Standard errors and 95% confidence intervals were obtained using the delta method. We defined influenza season based the percentage of medical visits for influenza-like illness in California as reported by the California Department of Public Health. Influenza season started when there were at least 2 consecutive weeks in which the percentage of medical visits for influenza-like illness exceeded 2.5%, and the season ended when there were at least 2 consecutive weeks in which the percentage was less than or equal to 2.5%.](pmed.1003238.g004){#pmed.1003238.g004}

Among all ages and across all 4 influenza seasons, the mean DID in length of influenza hospitalization was approximately 1 to 2.5 days lower in the intervention district versus the comparison district ([S8](#pmed.1003238.s014){ref-type="supplementary-material"} and [S9](#pmed.1003238.s015){ref-type="supplementary-material"} Figs). The incidence of influenza-related intensive care unit admissions was lower in the intervention site than in the comparison site in seasons 2014--2015, 2015--2016, and 2016--2017 and was similar in season 2017--2018 ([S10 Fig](#pmed.1003238.s016){ref-type="supplementary-material"}). The influenza-related mortality rate was slightly higher in the intervention site before the intervention and was lower in the 2014--2015, 2015--2016, and 2017--2018 influenza seasons ([S11 Fig](#pmed.1003238.s017){ref-type="supplementary-material"}). However, for all intensive care unit and mortality estimates, 95% confidence intervals for district-specific estimates overlapped. Our sensitivity analyses using alternative population denominators, influenza case definitions, and influenza season definitions yielded similar results overall ([S12](#pmed.1003238.s018){ref-type="supplementary-material"} and [S13](#pmed.1003238.s019){ref-type="supplementary-material"} Figs).

School absenteeism {#sec025}
------------------

In the 3 years prior to the Shoo the Flu program, during influenza season, the mean absence rate per 100 days in the intervention versus comparison district was 4.85 versus 5.84 for all-cause absences and 2.84 versus 2.81 for illness-specific absences ([S5 Table](#pmed.1003238.s027){ref-type="supplementary-material"}). The DID in mean illness-specific absence rate per 100 days was −0.16 (95% CI −0.54, 0.23; *p* = 0.425) in 2014--2015 and −0.34 (95% CI −0.78, 0.10; *p* = 0.130) in 2015--2016 ([Fig 5](#pmed.1003238.g005){ref-type="fig"}; [S5 Table](#pmed.1003238.s027){ref-type="supplementary-material"}). In 2016--2017 and 2017--2018, the DID in illness-specific absence rate per 100 days was lower in the intervention district compared to the comparison district (2016--2017 DID −0.63 \[95% CI −1.14, −0.13; *p* = 0.014\]; 2017--2018 DID −0.80 \[95% CI −1.28, −0.31; *p* = 0.001\]). The reduction in total illness-specific student absences during influenza season was 3,538 (95% CI 709, 6,366; *p* = 0.014) in 2016--2017 and 8,249 (95% CI 3,213, 13,285; *p* = 0.001) in 2017--2018 in the intervention district. For all-cause absences, the DID estimates during influenza season were not statistically significant in any years of the program. During the peak week of the influenza season, there was evidence of larger reductions in illness-specific absence rates in 2014--2015, 2016--2017, and 2017--2018, and there was a significant reduction in all-cause absences in 2017--2018 ([S5 Table](#pmed.1003238.s027){ref-type="supplementary-material"}). Our sensitivity analyses using alternative influenza season definitions were consistent with the primary analysis ([S14 Fig](#pmed.1003238.s020){ref-type="supplementary-material"}). Mean absence rates were not associated with the percentage of students in each school that participated in Shoo the Flu in 2014--2015 and 2015--2016. In 2017--2018, the school-level SLIV participation rate was associated with a modest reduction in the mean absence rate when adjusting for potential school-level confounders ([S15 Fig](#pmed.1003238.s021){ref-type="supplementary-material"}).

![Intervention effects on the school absence rate per 100 school days during influenza season.\
In (A), each difference-in-differences estimate compares the difference in mean absence rate in each district in a program influenza season compared to the 3 pre-program seasons (2011--2013); in (B), each difference-in-differences estimate compares the difference in total absence rate, which was calculated by multiplying difference-in-differences in mean absences by the total enrollment and total number of school days during influenza season each season. Difference-in-differences parameters remove any time-invariant differences between groups (measured or unmeasured). Parameters were estimated using a generalized linear model and were adjusted for month, student race, and grade. Standard errors and 95% confidence intervals account for clustering at the school level. We defined influenza season based the percentage of medical visits for influenza-like illness in California as reported by the California Department of Public Health. Influenza season started when there were at least 2 consecutive weeks in which the percentage of medical visits for influenza-like illness exceeded 2.5%, and the season ended when there were at least 2 consecutive weeks in which the percentage was less than or equal to 2.5%. Note: in 2011--2012, 2016--2017, and 2017--2018, the peak week of the percentage of influenza-like illness visits in California was the last week of December, which coincided with school breaks, so for the absentee analysis we shifted the peak week definition to the week before or after the school break (when both school districts were in session) that had the higher percentage of influenza-like illness visits.](pmed.1003238.g005){#pmed.1003238.g005}

We performed a negative control time period analysis, estimating DID outside influenza season, when we did not expect the intervention to affect absence rates. Overall, we did not see an effect on all-cause absences outside of influenza season. However, there were statistically significant reductions in illness-specific absences outside of influenza season in influenza seasons 2015--2016, 2016--2017, and 2017--2018 ([S16 Fig](#pmed.1003238.s022){ref-type="supplementary-material"}), suggesting that differential measurement error may have impacted the primary analysis. We explored the influence of outcome misclassification on our findings with a probabilistic bias analysis under assumed distributions of sensitivity and specificity of outcome classification. We found that the majority of bias-corrected DID estimates in 2016--2017 and 2017--2018 indicated a reduction in both types of absences in the intervention district ([S5 Appendix](#pmed.1003238.s006){ref-type="supplementary-material"} Figs B and C). These findings suggest that outcome misclassification was not strong enough to alter the scientific inferences in our primary analysis of absenteeism.

Discussion {#sec026}
==========

Here, we evaluated the impact of a city-wide SLIV intervention delivered to 95 or more elementary schools per season in a diverse, predominantly low-income city. During the first 2 years of SLIV, the program offered LAIV, which had low effectiveness \[[@pmed.1003238.ref057],[@pmed.1003238.ref058]\], and on the whole, we did not observe associations between SLIV and hospitalization or absence rates in those years. In the 2016--2017 and 2017--2018 influenza seasons, when the intervention delivered IIV and the vaccine was moderately effective \[[@pmed.1003238.ref040],[@pmed.1003238.ref059]\], we observed an association between SLIV and reduced illness-related school absences and reduced hospitalizations among age groups not targeted by SLIV, suggesting that the intervention produced indirect effects.

Unique strengths of our study design include the use of multivariate matching and a DID approach to minimize systematic differences between the intervention and comparison sites and the prespecification of our statistical analysis plan \[[@pmed.1003238.ref060]\]. Evaluating SLIV over multiple years enabled us to examine the impact of SLIV in influenza seasons with different levels of vaccine effectiveness, vaccine recommendations, and circulating strains of influenza. Furthermore, this study leveraged 3 distinct, independent data sources that provided internally consistent results.

The SLIV intervention was associated with increases in influenza vaccination coverage of up to 11 percentage points among elementary school students in the intervention site versus the comparison site. This increase in vaccination coverage is smaller than those reported in prior SLIV studies, which ranged from 7 to 41 percentage points. However, in most prior studies, coverage at baseline or in the comparison group was substantially lower than 50% \[[@pmed.1003238.ref016],[@pmed.1003238.ref017],[@pmed.1003238.ref019],[@pmed.1003238.ref021],[@pmed.1003238.ref023]--[@pmed.1003238.ref025],[@pmed.1003238.ref033]\], while in our study it was 53%--66%. It may be more difficult for SLIV to substantially increase coverage at moderate pre-intervention coverage levels. In addition, the switch from LAIV to IIV in the third year of the Shoo the Flu intervention may have inhibited larger increases in coverage because many children and/or caregivers prefer the nasal spray generally and in a school setting, and media coverage of poor LAIV effectiveness may have increased vaccine hesitancy for all influenza vaccine formulations. In the comparison site, the 10% reduction in vaccination coverage between 2015--2016 and 2016--2017, when LAIV was discontinued, was on par with the approximately 12% of students reported by caregivers to have been vaccinated with LAIV in 2014--2015 and 2015--2016 in that site ([S5 Fig](#pmed.1003238.s011){ref-type="supplementary-material"}; [S3 Table](#pmed.1003238.s025){ref-type="supplementary-material"}). Yet, vaccination coverage in the intervention district grew relative to the comparison district over time, in part because the comparison district coverage did not recover from the decline associated with the switch from LAIV to IIV vaccines. It is possible that coverage in the intervention district will continue to grow in future years as the intervention builds trust and recognition.

A key question is whether SLIV interventions increase vaccination coverage among students who would otherwise not be vaccinated, whether they merely shift vaccination location from healthcare providers to schools, or whether both occur. Interventions that vaccinate children who would otherwise not be vaccinated will have the largest impact on influenza transmission. Our findings suggest that both phenomena may have occurred in this study. Coverage was higher in the intervention versus comparison district in the final 2 years of the evaluation, suggesting that children who otherwise would not have been vaccinated were vaccinated by the SLIV intervention. In addition, the proportion of students vaccinated at school in the intervention district (24%--26% in the latter 2 years \[[S4 Fig](#pmed.1003238.s010){ref-type="supplementary-material"}\]) exceeded the difference in coverage between districts (7%--11%). While we cannot definitively determine what the vaccination coverage levels would have been in the intervention site in the absence of the SLIV intervention, these findings suggest that approximately 15% of students vaccinated by the SLIV intervention may otherwise have been vaccinated through other means. A limitation is that pre-intervention vaccination data were not available, so we were not able to conduct DID analyses to account for any pre-SLIV differences in vaccination coverage between districts.

Influenza vaccination coverage in the Shoo the Flu intervention site was 64%, which was up to 11% higher than in the comparison site and well within the 50%--70% range in which herd immunity is expected \[[@pmed.1003238.ref009],[@pmed.1003238.ref010]\]. We observed reductions in influenza hospitalization among non-elementary-school-aged community members in seasons with moderate vaccine effectiveness ([S4 Table](#pmed.1003238.s026){ref-type="supplementary-material"}). Indirect effects were strongest among individuals aged 65 years or older---the age group most vulnerable to influenza hospitalization and mortality. The magnitude of indirect effects we observed is similar to those of other SLIV interventions \[[@pmed.1003238.ref020],[@pmed.1003238.ref021],[@pmed.1003238.ref031]--[@pmed.1003238.ref033]\] and of interventions vaccinating children at any location \[[@pmed.1003238.ref061]\]. In addition, our results are highly consistent with mathematical models, which project that an increase from 40% to 60% coverage in children aged 6 months to 18 years would reduce influenza hospitalization among adults 19--64 years of age by 36% and adults 65 years or older by 33% \[[@pmed.1003238.ref014]\]. Our findings suggest that even modest increases in vaccination (i.e., up to 11%) associated with SLIV can produce meaningful community-wide reductions in influenza hospitalization, consistent with mathematical models \[[@pmed.1003238.ref062]\].

This analysis is subject to several limitations. First, although the reductions in illness-specific school absences we observed were of a similar magnitude to those reported in prior studies \[[@pmed.1003238.ref016]--[@pmed.1003238.ref019],[@pmed.1003238.ref026]--[@pmed.1003238.ref028]\], our finding of significant differences in absence rates outside of influenza season suggests that our absentee results may be subject to differential misclassification. It is possible that school-year- and school-district-specific differences unrelated to the SLIV intervention could explain these findings. For example, district-specific policies to decrease absences around school breaks (some of which coincide with influenza season) or at the beginning or the end of the school year (which is included in our negative control time period analysis) may have impacted our estimates in an unknown direction, especially if they differed before and during the SLIV intervention. In addition, parents may have attributed illness absences to a different reason, and such misclassification could have varied by district. Our probabilistic bias correction analysis suggested that correcting for misclassification would not change our conclusion that the SLIV intervention reduced illness-specific absences in 2016--2017 and 2017--2018.

Second, given that the SLIV intervention was delivered city-wide, it was not possible to conduct a randomized trial. The matched cohort design minimized differences in measured confounders between the intervention and comparison site, and DID analyses controlled for measured and unmeasured time-invariant confounding. Nevertheless, unmeasured time-dependent confounding could still bias this observational design. For example, the first year of the SLIV intervention coincided with the rollout of the preventive benefits of the Affordable Care Act, which may have jointly affected healthcare utilization and vaccination patterns in the study region.

Third, our vaccination coverage estimates relied on caregiver reporting, which is subject to inaccurate recall and low response rates. Prior studies report that caregiver recall of child influenza vaccination in the past season has a sensitivity of 88%--92% and a specificity of 82%--90% compared to medical records \[[@pmed.1003238.ref063]--[@pmed.1003238.ref065]\]. Coverage estimates for 2014--2015 and 2015--2016 may be more vulnerable to measurement error because they rely on a 2- to 3-year recall period. Overall, our vaccination coverage estimates were consistent with caregiver-reported national and California-specific estimates from the Centers for Disease Control and Prevention \[[@pmed.1003238.ref011],[@pmed.1003238.ref066]\]. Nevertheless, it is possible that caregiver recall in the intervention district differed from that in the comparison district; the presence of the SLIV intervention may have increased parents' likelihood of accurately recalling their child's vaccination status. It was not possible to validly compare our results to coverage estimates from the California Immunization Registry because prior to and during the SLIV intervention, many local vaccine providers did not consistently enter data into the registry as there is no mandate to do so in California, and there were differences in reporting rates between providers in the intervention and comparison site.

Finally, we did not have a direct measure of laboratory-confirmed influenza incidence in elementary school children or influenza vaccination coverage estimates among non-elementary-aged individuals; thus, it remains possible that factors other than the SLIV intervention could explain our findings. We were not able to link individuals between different data sources because personal identifiers were not available to us. Nevertheless, high levels of internal consistency across results from 3 independent data sources lend credence to the validity of our findings.

Conclusions {#sec027}
===========

Offering SLIV to all elementary schools in a large, urban district was associated with 7%--11% increases in vaccination, which were followed by meaningful reductions in illness-specific absences among school children and community-wide influenza hospitalization among those not targeted by the program, including the elderly, in 2016--2017 and 2017--2018. Our findings suggest that even modest increases in influenza vaccination above moderate coverage levels are associated with broad community-wide benefits.
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After the abstract, we will need to ask you to add a new and accessible \"author summary\" section in non-identical prose. You may find it helpful to consult one or two recent research papers published in PLOS Medicine to get a sense of the preferred style.

Please trim the introduction section of your paper.

We note that you refer to a prespecified analysis plan in the methods section of your main text, and ask that you highlight any non-prespecified analyses.

Please adapt the early part of your discussion section so that the first paragraph consists mainly of a summary of the study\'s findings.

Please adapt journal names where needed (e.g. \"PLoS ONE\" for reference 69; \"U S A\" needs to be added to reference 42). Several references are quoted as \"in press\", which can probably be removed if these are \"early online\" versions.

We ask you to add a completed checklist for the most appropriate reporting guideline as a supplementary document (referred to in your methods section), which may be STROBE or RECORD. In the checklist, please refer to individual items by section (e.g., \"Methods\") and paragraph number rather than by line or page numbers, as the latter generally change in the event of publication.

Comments from the reviewers:

\*\*\* Reviewer \#1:

The manuscript describes the results of a multi-year study to assess the community-wide impacts of a school-located influenza vaccination (SLIV) program that was introduced in the Oakland Unified School District (OUSD) starting in 2014. The study uses many sources of data to estimate various effects of the SLIV program over multiple years with multiple vaccines; this approach would likely appeal to the general readership of this journal. However, I have several major concerns with the manuscript.

1\. It is difficult to follow and keep track of the various endpoints, subgroups, stratified analyses, and sensitivity analyses, especially since neither the schematic of SLIV effects estimated in the study (Figure 1), nor the supplemental material (Appendix S4) include many of the analyses included in the abstract, results, and primary figures. For example, Figure 3 includes estimates among the elderly (not included in Figure 1) but does not include estimates among elementary-aged children (included in Figure 1). The Methods section and accompanying figures should be revised for completeness and clarity.

2\. There is a lack of consistency when referring the various definitions of the influenza season considered in this manuscript that should be resolved, including:

\- On page 11, the primary and pre-specified analysis defined the flu season starting when there were two consecutive weeks with %ILI reported to CDPH exceeding a given cutoff. In the primary manuscript, the cutoff of 2.5% was selected after comparing cutoffs of 2%, 2.5%, and 3%, as shown in Appendix S5. However, I do not see mention of alternative cutoffs in the analysis plan. Additionally, in Appendix S10 Fig 13, the caption suggests that the CDC flu season definition is the primary analysis.

\- Is California Emerging Infection Program\'s influenza season from Oct 1 through April 30 (Page 11, lines 231-232) the same as the period between week 40 and week 20 of each year (Page 13, line 269; Page 14, line 290), and CDC\'s standard definition (as referred to in Appendix S10 Fig 13)?

\- Finally, the sensitivity analysis for hospitalizations that restricted to the peak week of each influenza season is first introduced in the primary manuscript on Page 18, in the discussion of the results. Since this was prespecified, I would have expected it to be included in the discussion of the methods (it was for absenteeism).

3\. The analyses were designed to estimate incidence and absentee rates, but the authors sometimes report intervention effects in absolute numbers (including in the Abstract). The total numbers aren\'t interpretable until they are put into a broader context and the total numbers are a simple scaling of the estimates of the rates (Page 14, line 281). I don\'t mind when the estimated total numbers are presented along with the estimated rates (as in Figure 3), but I am not sure how to interpret results when only the total numbers are presented. Why report only the results in total numbers when the rates are directly comparable?

4\. There are several comparisons made, and while p-values are not presented the authors do describe results as statistically significant, or significantly different. How is statistical significance assessed throughout the manuscript? And was there any adjustment for multiple testing?

5\. The claim that the school district catchment areas summarized in Table 1 are \"similar\" (Page 16, line 323) seems overly broad when there are noticeable differences between the two areas. The differences in median income, percentage of families below the poverty level, and a proportion of the population with college degrees could be associated with the outcomes of interest. If these differences are indicative of systemic difference between the two areas, could these differences confound the estimates of the SLIV program effects?

6\. It looks like the Intervention/Comparison labels at the top of Appendix S3 Table 1 are flipped compared to other summaries of the two school districts, including those in Appendix S6 and Appendix 1 in the pre-specified analysis plan. Please check the column labels. Additionally, based on the description of the matching algorithm on starting on Page 8, line 159, I was expecting Appendix S3 Table 1 to also include summaries of school-level percentages of English language learners and students receiving free lunches.

7\. Why are 95% CIs not reported along with vaccination coverage estimates (pages 16-17, Appendix S6)? Since they are reported in the Abstract and described in the Statistical Analysis section (Page 12, line 235), they should be reported throughout the manuscript.

8\. The weekly time series in Fig 2 lets us assess whether the trends in the incidence of flu-hospitalization are parallel within a given flu season, but the analyses are done comparing annual flu seasons (so cumulative incidence for the 2015-16 season). How do the weekly (or daily in the case of absenteeism) time series allow us to assess how reasonable the parallel trend assumption is for the DID analyses that are done? And are there similar assessments for the stratified analyses? Lastly, why were school absence trends used to assess whether the equal trend assumption was met for the analyses of influenza hospitalizations (Page 13, line 257)?

9\. Based on the negative control analysis for absenteeism, the authors conclude that differential measurement error may impact the primary analysis (Page 22, line 454). The misclassification analysis gets a lot of attention, but the results of negative control analysis could be explained by many other possible sources of unmeasured confounding. Why was misclassification the only source considered? Could the differences seen in Table 1, along with the results of the negative control analysis be indicative of a poor match for the comparison district? Or could the demographics have shifted differentially in the two districts?

Minor comments:

\- In Table 1, how are the 95% CI\'s computed for the Median household income?

\- One school dropped out of the vaccine coverage survey, how is that school and its matched pair accounted for in the participant flow in Appendix S9? Where there originally 45 or 46 schools?

\- The categories for the analysis of vaccine coverage by caregiver education level (Appendix S10, Figure 4) and Page 17, line 352 should match than those reported earlier in Appendix S6 and be discussed consistently in the manuscript.

\- Do the estimates in Figure 2 include ICU admissions? Are these total numbers, standardized for potential differences in age groups across the two areas? I would also expect to see these trends for the age subgroups used to obtain the estimates in Figure 3.

\- How was illness-specific absence defined?

\- Does the school-absenteeism analysis use only the matched schools in each district, or all schools in both districts?

\- The caption for Figure 4 should be edited to reflect the definition of flu season that is used.

\- What are the adjusted and unadjusted analyses presented in Appendix S10 Figure 14? And the accompanying caption should clearly define the flu season definitions.

\- The pre-specified plan described the study as a retrospective matched cohort study, but the manuscript refers to the study as prospective. Can you please clarify?

\- How were the estimates of vaccine effectiveness (page 7 and Appendix S2) obtained?

\- The manuscript described power calculations for the vaccine coverage survey but similar computations for the laboratory-confirmed influenza hospitalizations and school absenteeism endpoints (those can be found in the pre-specified analysis plan). These should be organized better.

\- I could not find a pre-specified plan for the matching of cohorts or for of the vaccine coverage survey.

\- I could not find the code to replicate the analyses online.

\*\*\* Reviewer \#2:

In this interesting study, the authors evaluated the impact of school-located influenza vaccination (SLIV) programs implemented in \>95 preschools and elementary schools in Oakland, CA during the 2014-15 to 2017-18 influenza seasons. The authors used multiple data sources to examine vaccine coverage, school absences, and laboratory-confirmed influenza hospitalizations. They used a matched cohort design with a comparison community, and used a difference-in-differences (DID) approach to the analyses for hospitalization incidence and absenteeism.

I was impressed by: 1) the inclusion of multiple outcomes determined from independent data sources; 2) the rigor and comprehensiveness of the analyses conducted (with numerous sensitivity and subgroup analyses), and how the authors addressed a number of challenges along the way; 3) the interesting findings of the effects of the program against relatively specific outcomes when differences in vaccine coverage were observed and the vaccine was effective; 4) the appropriate interpretation of the results and the fulsome discussion; and 5) the quality of the writing.

I believe this manuscript would be suitable for publication with just a few minor changes:

1\. Abstract Line 30: I believe the surveys should be labelled as 2017 and 2018 rather than 2016 and 2017.

2\. Abstract, Lines 45-49: I am wondering if it would be better to report the reductions in outcomes as rates rather than absolute counts. I can appreciate the desire to report the reductions as absolute counts, but would like to hear the authors\' rationale for choosing counts over rates.

3\. S10 Appendix Table 1: DID in total hospitalizations, Elderly, 2016-17: should be -5 rather than 5. In later rows, the authors should use 2014-15, 2015-16, etc. for the row headings, instead of 1415, 1516, etc. for consistency.

4\. Line 406: should be S10 Supplement, not S11 Supplement

Jeff Kwong

\*\*\* Reviewer \#3:

GENERAL COMMENTS

This is a very nicely designed study, using aa matched prospective cohort design (matching school districts) and a DID analysis to evaluate the impact on school-located influenza vaccination (SLIV) on: (a) influenza vaccination rates of schoolchildren, (b) school absenteeism, (c) indirect effects (child and adult lab-confirmed hospitalization rates). The study found that during the first two years of SLIV, self-reported vaccination coverage was not higher in intervention schools (when 22-28% of children were vaccinated in school) and flu VE was suboptimal, but in the latter two years (2016/17 and 2017/18) it was higher and there was also a DID difference in the expected direction for school absenteeism and pediatric and adult hospitalizations (same % of children receiving SLIV, but these 2 years the vaccine was more effective).

The study is novel in that it is methodologically rigorous yet also measures school absenteeism and hospitalizations as indirect outcomes (most prior RCTs of SLIV have not).The study is limited by inherent weaknesses of the design (namely lack of an RCT, self-reported influenza vaccinations); however given the fact that in today\'s world it is quite unusual to be able to randomize schools and to conduct such large studies within an RCT, the study and findings are important. The authors do a nice job describing the limitations.

The findings are complicated by multiple co-occurring events or findings---across the 4 years, when similar numbers of students received SLIV vaccinations:

\* Overall influenza vaccination rates were lower in intervention schools in Year 1, no different in Year 2, but then much higher in years 3-4 but almost entirely due to vaccination rates in control school districts dropping precipitously rather than vaccination rates rising in intervention schools presumably due to SLIV. This suggests the possibility that it was not SLIV that caused these findings, but rather some unknown drop in vaccination rates in the control school district.

\* LAIV (which was given in \>85% of SLIV cases) was minimally effective in year 1, not effective in year 2, but IIV which was given exclusively in years 3-4 was effective those years based on national data. So the study findings would predict no impact in years 1-2, but an impact in years 3-4 based merely on national VE data---but only if vaccination rates are indeed higher in intervention vs control school districts.

All of this makes it challenging to follow and understand the findings; but having said that the paper is extremely well written given these constraints.

One key problem I see is self-reported vaccination rates, and particularly a single survey to assess flu vaccinations received over 3 years---the accuracy of this is unclear. Why was CA immunization registry data not assessed to at least verify accuracy? It is possible that recall is better for SLIV districts because parents needed to give consent for vaccination---causing a potential positive (not conservative) bias in ascertainment of vaccination rates. Also the low response rates for the parent surveys, and much lower response rates for the intervention schools (28% vs 38% in control schools) makes these findings a bit more suspect, though I don\'t have apriori thoughts about the possible direction of bias.

This is an enormous manuscript; difficult to wade through. I would suggest eliminating race/ethnicity comparisons throughout to make it a bit less cumbersome. I don\'t see apriori hypotheses for race/ethnicity, and it is confusing since vaccine uptake is lower among black patients and samples get small for the surveys.

SPECIFIC COMMENTS

INTRODUCTION

This section is well written and includes many SLIV-related publications. It also lays the rationale well for this current study- namely that the prior RCTs tended to not study school absences or flu-related illnesses, and the prior studies that did evaluate flu-related hospitalizations or illnesses had somewhat conflicting findings.

METHODS

SLIV intervention:

This section is well written.

Influenza VE:

Although space is of concern, since so much of the findings depend on the national vaccine effectiveness, I suggest either adding the table to the main article (rather than appendix) or stating numbers in the text---eg VE for SLIV in Years 1-2, and for IIV in years 3-4.

Study Design:

The matching of intervention vs control school districts (cities) was done carefully.

The vaccine coverage survey is problematic since there was one survey that asked parents to recall influenza vaccinations for the prior 3 years (2014-15, 2015-16, 2016-17 flu vaccination seasons), and a second survey that asked about 2017-2018. While prior studies have found good recollection of parental reports of flu vaccinations received in the past vaccination season, I am unsure how accurate self-report would be for 3 seasons. Having said that, there may not be bias in accuracy between intervention and control schools, but there may be bias if the SLIV process (and consent for SLIV) spurred recall of vaccinations received. This is particularly important because the entire study seems to rest upon a DROP in vaccination rates in the control city (school district)- for unclear reasons.

The analytic approach is otherwise fine. Of note, I did not understand in the method section what differential ascertainment of school absences (measurement error) meant.

RESULTS

Influenza vaccination coverage:

This section is mostly fine, except I would point out that the difference in coverage between SLIV and control districts was almost entirely due to a DROP in coverage in the control district rather than a rise in coverage in SLIV schools. This lack of a rise in SLIV schools suggests that most SLIV vaccinations were simply substituting for vaccinations otherwise given in doctor\'s offices. It also brings up the possibility that something unusual happened in the control city to account for the drop in vaccination rates and that the ultimate findings might not be due to SLIV.

Influenza Hospitalization

Hospitalization rates actually ROSE in both cities during the time of a moderately effective vaccine, and the major reason for the DID differences is that they rose markedly in the comparison city in 2016-2017 and 2017-2018 (this is also perhaps related to the marked drop in influenza vaccination rates in that city).

Absenteeism:

I would add the pre-intervention data to Figure 4, rather than keeping it only in the appendix.

One suggestion is to delete race/ethnicity subgroup analyses in this very extensive manuscript. There is some benefit to keeping race/ethnicity but it could be in a separate manuscript.

I do not follow the outcome misclassification section when only reading the text. I understand there was a peculiar decrease in illness-specific school absences outside of the flu season, and this is problematic, but the explanation was not sufficient for me to understand what was actually done \"under assumed distributions of sensitivity and specificity\" or how that reassured the authors that this did not influence the findings sufficiently.

DISCUSSION

In paragraph 2 the authors state that the vaccination rates for the intervention city was higher than rates for the control city because the latter \"did not recover from the decline associated with the switch from LAIV to IIV vaccines.\" This might be true, but nationally vaccination rates did not drop more than 1-2 percentage points during this time, and the authors do not show data to substantiate this claim. For example, how much LAIV was used in the control city prior to its termination? Is this all speculation or are there data? Does CAIR provide any answers---ie what was the city-wide vaccination rates in CAIR before and after this time period? I am worried that something else, unmeasured, may be going on.

The paragraph on potential substitution is fine, but perhaps over-calling the impact of SLIV, since it implies that without SLIV the coverage rate in the intervention city of Oakland would have dropped markedly. This did not occur nationally (flu vaccination rates for 5-12yr olds dropped by 2 percentage points between 2015/16 and 2016/17) or I believe statewide across California---so why would one expect it to drop so much?

Overall the rest of the discussion section was well done.

\*\*\*

Any attachments provided with reviews can be seen via the following link:
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10.1371/journal.pmed.1003238.r002
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12 Jun 2020

Dear Dr. Benjamin-Chung,

Thank you very much for re-submitting your manuscript \"Evaluation of a city-wide school-located influenza vaccination program in Oakland, California with respect to vaccination coverage, school absences, and laboratory-confirmed influenza: a matched cohort study ​\" (PMEDICINE-D-19-04321R1) for review by PLOS Medicine.

I have discussed the paper with my colleagues and the academic editor and it was also seen again by xxx reviewers. I am pleased to say that provided the remaining editorial and production issues are dealt with we are planning to accept the paper for publication in the journal.

The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:

\[LINK\]

Our publications team (<plosmedicine@plos.org>) will be in touch shortly about the production requirements for your paper, and the link and deadline for resubmission. DO NOT RESUBMIT BEFORE YOU\'VE RECEIVED THE PRODUCTION REQUIREMENTS.

\*\*\*Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.\*\*\*

In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers\' and editors\' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.

Please also check the guidelines for revised papers at <http://journals.plos.org/plosmedicine/s/revising-your-manuscript> for any that apply to your paper. If you haven\'t already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract.

We expect to receive your revised manuscript within 1 week. Please email us (<plosmedicine@plos.org>) if you have any questions or concerns.

We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.

If you have any questions in the meantime, please contact me or the journal staff on <plosmedicine@plos.org>.

We look forward to receiving the revised manuscript by Jun 19 2020 11:59PM.

Sincerely,

Thomas McBride, PhD

Senior Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Requests from Editors:

1- Thank you for editing the Discussion for causal language. Please also edit the first sentence of the Abstract Conclusions: "A city-wide SLIV intervention in a large, diverse urban population \*was associated with a decrease in\* the incidence of laboratory-confirmed influenza hospitalization in all age groups and \*a decrease in\* illness-specific school absence rates among students during seasons\... "

2- Similarly, in the Discussion Conclusions: "Offering school-located influenza vaccination to all elementary schools in a large, urban district led to 7-11% \*was associated with\* increases in vaccination, which \*was followed by\* meaningful reductions in community-wide reductions in influenza hospitalization and illness-specific absences among school children among those not targeted by the program, including the elderly."

3- Introduction, beginning of the 3rd paragraph: "\...as \*a\* strategy..."

4- Introduction, end of the 3rd paragraph, please edit to read: "To our knowledge, no prior studies...." or similar.

5- Thank you for noting that documented informed consent was waived, please specify that it was the Committee for the Protection of Human Subjects that provided this waiver (I'm assuming that's who provided the waiver).

6- Please also move the Ethical Statement towards the beginning of the Methods (so it appears as the first or second section).

7- Thank you for providing the completed STROBE checklist. Please add the following statement, or similar, to the Methods: \"This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline (S\_ Checklist).\"

8- When presenting the demographic information in the Results section, please include the 95%CIs.

9- Please adjust the wording at lines 57, 522 and 623 to more clearly reflect that the reduction in admission was not significant until years 3 and 4.

10- Please add the STROBE checklist to the list of Supporting Information items at the end of the main text.

11- Please use the \"Vancouver\" style for reference formatting, and see our website for other reference guidelines <https://journals.plos.org/plosmedicine/s/submission-guidelines#loc-references>

Comments from Reviewers:

Reviewer \#1: The authors have done a great job revising the manuscript to address the reviewer comments and I appreciate the more streamlined manuscript. I think this manuscript is suitable for publication, however I do have one minor comment:

\- The parallel trend assumption for the DID analyses is untestable and I would suggest the authors soften the language to something like \"the data indicates the assumption of equal trends is reasonable\", rather than \"equal trends assumption was met\" (lines 295 and 324 for example).

Reviewer \#2: The authors have addressed my comments. I have no further comments.

Reviewer \#3: This is a very nicely designed study, using a matched prospective cohort design (matching school districts) and a DID analysis to evaluate the impact on school-located influenza vaccination (SLIV) on: (a) influenza vaccination rates of schoolchildren, (b) school absenteeism, (c) indirect effects (child and adult lab-confirmed hospitalization rates). The study is novel particularly in assessing \"b\" and \"c\" since more rigorous studies without the limitations below have assessed \"a\".

The authors dis a very nice job responding to the many critiques. The two major critiques I had included (1) concern that their study rests on a drop in self-reported influenza vaccination coverage among comparison schools rather than an increase in SLIV schools and (2) self-reported influenza vaccination without any validation via CAIR or other methods.

The authors responded to \#1 by highlighting the large % of vaccines given via LAIV in 2014-15 and 2015-16 (prior to it being discontinued) and the drop in vaccination rate in comparison schools being approximately the same as the proportion that had been given via LAIV. This is plausible. Apparently CAIR was not sufficiently complete to be used as a validation for self-reported vaccination rates, and it is difficult to see why there would be such a large difference in the bias in self-reported rates for comparison vs control schools. This is a limitation, but I feel it likely did not affect the results substantially.

Overall this is a very nice paper and revision.

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003238.r004
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Dear Dr. Benjamin-Chung,

On behalf of my colleagues and the academic editor, Dr. Mirjam Kretzschmar, I am delighted to inform you that your manuscript entitled \"Evaluation of a city-wide school-located influenza vaccination program in Oakland, California with respect to vaccination coverage, school absences, and laboratory-confirmed influenza: a matched cohort study ​\" (PMEDICINE-D-19-04321R2) has been accepted for publication in PLOS Medicine.

PRODUCTION PROCESS

Before publication you will see the copyedited word document (in around 1-2 weeks from now) and a PDF galley proof shortly after that. The copyeditor will be in touch shortly before sending you the copyedited Word document. We will make some revisions at the copyediting stage to conform to our general style, and for clarification. When you receive this version you should check and revise it very carefully, including figures, tables, references, and supporting information, because corrections at the next stage (proofs) will be strictly limited to (1) errors in author names or affiliations, (2) errors of scientific fact that would cause misunderstandings to readers, and (3) printer\'s (introduced) errors.

If you are likely to be away when either this document or the proof is sent, please ensure we have contact information of a second person, as we will need you to respond quickly at each point.

PRESS

A selection of our articles each week are press released by the journal. You will be contacted nearer the time if we are press releasing your article in order to approve the content and check the contact information for journalists is correct. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact.

PROFILE INFORMATION

Now that your manuscript has been accepted, please log into EM and update your profile. Go to <https://www.editorialmanager.com/pmedicine>, log in, and click on the \"Update My Information\" link at the top of the page. Please update your user information to ensure an efficient production and billing process.

Thank you again for submitting the manuscript to PLOS Medicine. We look forward to publishing it.

Best wishes,

Thomas McBride, PhD

Senior Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)
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